1. Dengue vaccine: WHO position paper – July 2016. Weekly epidemiological record 2016; 91(30): 349–64.
2. World Health Organization. Global vaccine safety blueprint. Available at http://extranet.who.int/iris/restricted/bitstream/10665/70919/1/WHO_IVB_12.07_eng.pdf?ua=1. [accessed October 2016].
3. For highly endemic settings (e.g. seroprevalence at 9 years of age of approximately 90% or greater), modelling predicts vaccination at 9 years of age will maximize programme impact. In settings where seroprevalence at 9 years of age is between 50% and 90%, higher impact may be achieved with vaccination at 11–14 years of age.
4. Flasche S, et al., Comparative modelling of dengue vaccine public health impact. Available at http://www.who.int/immunization/sage/meetings/2016/april/2_CMDVI_Report_FINAL.pdf. [accessed October 2016].
5. “Administration of multiple injectable vaccines in a single visit” in meeting of the strategic advisory group of experts on immunization, April 2015: conclusions and recommendations. Weekly Epidemiological Record 2015; 90(22): 261–78.